Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 283

1.

A clinical tool for predicting survival in ALS.

Knibb JA, Keren N, Kulka A, Leigh PN, Martin S, Shaw CE, Tsuda M, Al-Chalabi A.

J Neurol Neurosurg Psychiatry. 2016 Jul 4. pii: jnnp-2015-312908. doi: 10.1136/jnnp-2015-312908. [Epub ahead of print]

PMID:
27378085
2.

Association of a Locus in the CAMTA1 Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis.

Fogh I, Lin K, Tiloca C, Rooney J, Gellera C, Diekstra FP, Ratti A, Shatunov A, van Es MA, Proitsi P, Jones A, Sproviero W, Chiò A, McLaughlin RL, Sorarù G, Corrado L, Stahl D, Del Bo R, Cereda C, Castellotti B, Glass JD, Newhouse S, Dobson R, Smith BN, Topp S, van Rheenen W, Meininger V, Melki J, Morrison KE, Shaw PJ, Leigh PN, Andersen PM, Comi GP, Ticozzi N, Mazzini L, D'Alfonso S, Traynor BJ, Van Damme P, Robberecht W, Brown RH, Landers JE, Hardiman O, Lewis CM, van den Berg LH, Shaw CE, Veldink JH, Silani V, Al-Chalabi A, Powell J.

JAMA Neurol. 2016 Jul 1;73(7):812-20. doi: 10.1001/jamaneurol.2016.1114.

PMID:
27244217
3.

Analysis of terms used for the diagnosis and classification of amyotrophic lateral sclerosis and motor neuron disease.

Rutter-Locher Z, Turner MR, Leigh PN, Al-Chalabi A.

Amyotroph Lateral Scler Frontotemporal Degener. 2016 May 18:1-5. [Epub ahead of print]

PMID:
27188215
4.

Syntactic processing as a marker for cognitive impairment in amyotrophic lateral sclerosis.

Tsermentseli S, Leigh PN, Taylor LJ, Radunovic A, Catani M, Goldstein LH.

Amyotroph Lateral Scler Frontotemporal Degener. 2015;17(1-2):69-76. doi: 10.3109/21678421.2015.1071397. Epub 2015 Aug 24.

5.

Regionality of disease progression predicts prognosis in amyotrophic lateral sclerosis.

van der Kleij LA, Jones AR, Steen IN, Young CA, Shaw PJ, Shaw CE, Leigh PN, Turner MR, Al-Chalabi A.

Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):442-7. doi: 10.3109/21678421.2015.1051987. Epub 2015 Jun 17.

PMID:
26083873
6.

Recognising facial onset sensory motor neuronopathy syndrome: insight from six new cases.

Broad R, Leigh PN.

Pract Neurol. 2015 Aug;15(4):293-7. doi: 10.1136/practneurol-2014-000984. Epub 2015 May 19.

PMID:
25991863
7.

Decision Making About Gastrostomy and Noninvasive Ventilation in Amyotrophic Lateral Sclerosis.

Martin NH, Lawrence V, Murray J, Janssen A, Higginson I, Lyall R, Burman R, Leigh PN, Al-Chalabi A, Goldstein LH.

Qual Health Res. 2016 Aug;26(10):1366-81. doi: 10.1177/1049732315583661. Epub 2015 Apr 27.

PMID:
25918114
8.

Accepting or declining non-invasive ventilation or gastrostomy in amyotrophic lateral sclerosis: patients' perspectives.

Greenaway LP, Martin NH, Lawrence V, Janssen A, Al-Chalabi A, Leigh PN, Goldstein LH.

J Neurol. 2015;262(4):1002-13. doi: 10.1007/s00415-015-7665-z. Epub 2015 Feb 17.

PMID:
25683760
9.

Impact commentaries. Subacute necrotising encephalomyelopathy (Leigh's disease; Leigh syndrome).

Leigh PN, Al-Sarraj S, DiMauro S.

J Neurol Neurosurg Psychiatry. 2015 Apr;86(4):363-5. doi: 10.1136/jnnp-2012-304601. Epub 2015 Jan 13. No abstract available.

10.

Mitochondrial abnormalities and low grade inflammation are present in the skeletal muscle of a minority of patients with amyotrophic lateral sclerosis; an observational myopathology study.

Al-Sarraj S, King A, Cleveland M, Pradat PF, Corse A, Rothstein JD, Leigh PN, Abila B, Bates S, Wurthner J, Meininger V.

Acta Neuropathol Commun. 2014 Dec 14;2:165. doi: 10.1186/s40478-014-0165-z.

11.

Cortical thickness, surface area and volume measures in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.

Worker A, Blain C, Jarosz J, Chaudhuri KR, Barker GJ, Williams SC, Brown R, Leigh PN, Simmons A.

PLoS One. 2014 Dec 2;9(12):e114167. doi: 10.1371/journal.pone.0114167. eCollection 2014.

12.

Diffusion tensor imaging of Parkinson's disease, multiple system atrophy and progressive supranuclear palsy: a tract-based spatial statistics study.

Worker A, Blain C, Jarosz J, Chaudhuri KR, Barker GJ, Williams SC, Brown RG, Leigh PN, Dell'Acqua F, Simmons A.

PLoS One. 2014 Nov 18;9(11):e112638. doi: 10.1371/journal.pone.0112638. eCollection 2014.

13.

Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study.

Al-Chalabi A, Calvo A, Chio A, Colville S, Ellis CM, Hardiman O, Heverin M, Howard RS, Huisman MH, Keren N, Leigh PN, Mazzini L, Mora G, Orrell RW, Rooney J, Scott KM, Scotton WJ, Seelen M, Shaw CE, Sidle KS, Swingler R, Tsuda M, Veldink JH, Visser AE, van den Berg LH, Pearce N.

Lancet Neurol. 2014 Nov;13(11):1108-13. doi: 10.1016/S1474-4422(14)70219-4. Epub 2014 Oct 7.

14.

C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: a genome-wide meta-analysis.

Diekstra FP, Van Deerlin VM, van Swieten JC, Al-Chalabi A, Ludolph AC, Weishaupt JH, Hardiman O, Landers JE, Brown RH Jr, van Es MA, Pasterkamp RJ, Koppers M, Andersen PM, Estrada K, Rivadeneira F, Hofman A, Uitterlinden AG, van Damme P, Melki J, Meininger V, Shatunov A, Shaw CE, Leigh PN, Shaw PJ, Morrison KE, Fogh I, Chiò A, Traynor BJ, Czell D, Weber M, Heutink P, de Bakker PI, Silani V, Robberecht W, van den Berg LH, Veldink JH.

Ann Neurol. 2014 Jul;76(1):120-33. doi: 10.1002/ana.24198. Epub 2014 Jun 27.

15.

Evidence of an environmental effect on survival in ALS.

Keren N, Scott KM, Tsuda M, Barnwell J, Knibb JA, Ellis CM, Leigh PN, Shaw CE, Al-Chalabi A.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):528-33. doi: 10.3109/21678421.2014.911326. Epub 2014 May 27.

PMID:
24862874
16.

Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial.

Meininger V, Pradat PF, Corse A, Al-Sarraj S, Rix Brooks B, Caress JB, Cudkowicz M, Kolb SJ, Lange D, Leigh PN, Meyer T, Milleri S, Morrison KE, Orrell RW, Peters G, Rothstein JD, Shefner J, Lavrov A, Williams N, Overend P, Price J, Bates S, Bullman J, Krull D, Berges A, Abila B, Meno-Tetang G, Wurthner J.

PLoS One. 2014 May 19;9(5):e97803. doi: 10.1371/journal.pone.0097803. eCollection 2014.

17.

Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale.

Balendra R, Jones A, Jivraj N, Knights C, Ellis CM, Burman R, Turner MR, Leigh PN, Shaw CE, Al-Chalabi A.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):279-84. doi: 10.3109/21678421.2014.897357. Epub 2014 Apr 10.

PMID:
24720420
18.

Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis.

Jones AR, Jivraj N, Balendra R, Murphy C, Kelly J, Thornhill M, Young C, Shaw PJ, Leigh PN, Turner MR, Steen IN, McCrone P, Al-Chalabi A.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):285-91. doi: 10.3109/21678421.2013.872149. Epub 2014 Feb 7.

PMID:
24641613
19.

Psychological as well as illness factors influence acceptance of non-invasive ventilation (NIV) and gastrostomy in amyotrophic lateral sclerosis (ALS): a prospective population study.

Martin NH, Landau S, Janssen A, Lyall R, Higginson I, Burman R, McCrone P, Sakel M, Ellis CM, Shaw CE, Al-Chalabi A, Leigh PN, Goldstein LH.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5-6):376-87. doi: 10.3109/21678421.2014.886700. Epub 2014 Mar 6.

PMID:
24597488
20.

Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials.

Balendra R, Jones A, Jivraj N, Steen IN, Young CA, Shaw PJ, Turner MR, Leigh PN, Al-Chalabi A; UK-MND LiCALS Study Group, Mito Target ALS Study Group.

J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):45-9. doi: 10.1136/jnnp-2013-306865. Epub 2014 Jan 24.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk